- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05135910
To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis
An Open Label Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Hallux Terbinafine Subungual Gel Administered to the Toenail Bed of Patients With Distal-Lateral Subungual Onychomycosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Efficacy: To identify patients achieving Complete Cure in the target toenail at Week 52.
Secondary Efficacy: To identify patients that have achieved 1) Clinical Cure, 2) Mycological Cure, and/or 3) Positive Response in the target toenail at Week 52.
Plasma Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in a subpopulation of patients over the study period.
Nail Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in distal nail clippings in patients over the study period.
HSG Safety and Tolerability Profile: To establish from plasma pharmacokinetics, related adverse events, treatment site reactions, pain, clinically significant changes in medical condition and/or medications, and clinically significant changes in liver function, serum chemistry, urinalysis, and complete blood count over the study period.
Subungual Topical Procedure: To establish the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments, the Investigator will record at selected time points 1) nail measurements indicating progressive clearing, 2) the ease and depth of each topical administration, 3) the investigational drug volume administered each treatment, and 4) patient tolerability.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mark Taylor
- Phone Number: 949-637-4656
- Email: mark@halluxinc.com
Study Locations
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- OrthoArizona - East Valley Foot & Ankle Specialists
-
-
Colorado
-
Parker, Colorado, United States, 80134
- Front Range Foot and Ankle Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Oregon Dermatology & Research Center
-
-
Texas
-
College Station, Texas, United States, 77845
- J&S Studies
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and females 18 - 75 years of age inclusive
- Patients with DLSO of at least one great toe
- Patients with DLSO in the target toe confirmed by positive KOH and positive fungal culture for dermatophytes
- Willingness to abstain from pedicures, nail clipping, or application of nail polish or nail cosmetics to their toenails over the study period
Exclusion Criteria:
- History of any significant chronic fungal disease other than onychomycosis or an immunocompromised condition
- Any previous surgery to or abnormalities of the target toe that in the investigator's opinion could prevent the toenail surface area from clearing even if eradication of the DLSO infection is achieved
- Participation in another clinical study of an investigational drug or device within 3 months of screening
- No administration of oral terbinafine or another oral antifungal within 6 months of screening
- No topical antifungal used for onychomycosis or a dermatophyte infection (i.e. tinea pedis) within 3 months of screening
- No uncontrolled diabetes mellitus
- No severe psoriasis or severe atopic dermatitis
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSG
Hallux terbinafine subungual gel
|
Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Cure at Week 52 in the Target Toe
Time Frame: Week 52
|
Complete Cure is defined as 1) 100% healthy, clear nail, and 2) negative mycology.
Healthy, clear nail is absent any disease involvement attributable to DLSO and is determined by Investigator Global Assessment (IGA).
Negative mycology is defined as zero visualization of septate hyphae by KOH microscopy (negative KOH) combined with a fungal culture negative for causal dermatophytes (negative fungal culture).
|
Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Cure in the Target Toe
Time Frame: Week 52
|
100% healthy, clear nail
|
Week 52
|
Mycological Cure in the Target Toe
Time Frame: Week 52
|
Negative KOH, negative fungal culture
|
Week 52
|
Positive Response in the Target Toe
Time Frame: Week 52
|
≥ 80% decrease in disease involvement
|
Week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Pharmacokinetics
Time Frame: Week 52
|
To characterize plasma concentrations of terbinafine and metabolite from a subset of patients over the study period
|
Week 52
|
Nail Pharmacokinetics
Time Frame: Week 52
|
To characterize nail concentrations of terbinafine and metabolite from patients over the study period
|
Week 52
|
Subungual Topical Procedure
Time Frame: Week 44
|
To evaluate the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments to the target toe over 44 weeks.
Nail measurements indicating progressive clearing are recorded from an Investigator Global Assessment scale referencing % disease involvement corroborated by nail image analysis.
The ease and durability of subungual topical treatment is established using a 5-point Likert Scale.
Patient local tolerability is established using a Treatment Site Assessment Scale and Pain Intensity Scale.
|
Week 44
|
Patient Global Assessment
Time Frame: Week 52
|
To establish each patient's impression of DLSO improvement in their target toe over the study period, patients will reference the following scale (0 = clear of DLSO, 1 = marked improvement of DLSO, 2 = moderately improved DLSO, 3 = slightly improved DLSO, 4 = unchanged, 5 = worse)
|
Week 52
|
Safety and Tolerability: Established from patient incidence of Treatment-Emergent Adverse Events
Time Frame: Monitored from screening visit to end of study visit (Week 52)
|
Indicated by the number of patients with treatment-related adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE)
|
Monitored from screening visit to end of study visit (Week 52)
|
Safety and Tolerability: Established from clinical laboratory results
Time Frame: Monitored at selected time points from screening visit to end of study visit (Week 52)
|
Indicated by clinically significant changes in patient liver function, serum chemistry, urinalysis, and complete blood count over the study period
|
Monitored at selected time points from screening visit to end of study visit (Week 52)
|
Safety and Tolerability: Established from patient reported medical condition and use of medications
Time Frame: Monitored from screening visit to end of study visit (Week 52)
|
Monitored by assessing clinically significant changes in patient medical condition and/or use of medications over the study period
|
Monitored from screening visit to end of study visit (Week 52)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Phoebe Rich, MD, Oregon Dermatology and Research Center
- Principal Investigator: Lewis H. Freed, DPM, OrthoArizona, East Valley Foot & Ankle Specialists
- Principal Investigator: Terry M. Jones, MD, J&S Studies
- Principal Investigator: Daniel P. Mallett, DPM, Front Range Foot and Ankle Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSG-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis of Toenail
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
Mediprobe Research Inc.Emblation LimitedRecruiting
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Erchonia CorporationWithdrawnOnychomycosis of ToenailUnited States
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Chulalongkorn UniversityKing Chulalongkorn Memorial HospitalUnknown
-
Next Science TMDoctors Research Network; Tissue Analytics; NTS VenturesUnknown
Clinical Trials on Hallux Terbinafine Subungual Gel
-
Transport PharmaceuticalsCompleted
-
University of Rome Tor VergataRecruitingOnychomycosis | Nail Diseases | Resistant InfectionItaly